Gilead Sciences Inc.’s $11 billion bet on Kite Pharma Inc. is poised to pay off, with the approval Wednesday of Kite’s flagship cell-therapy treatment for advanced lymphoma patients.
MarketWatch.com - Top Stories, MarketWatch
Wed, 10/18/2017 - 3:20pm
Gilead Sciences Inc.’s $11 billion bet on Kite Pharma Inc. is poised to pay off, with the approval Wednesday of Kite’s flagship cell-therapy treatment for advanced lymphoma patients.